BZ019
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BZ019, covering 2022-07-25 to 2026-02-11. Get the full timeline:
Most recent: Clinical Trial Update: Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma [Phase 1]